Dihydroartemisinin, an anti-malaria drug, suppresses estrogen deficiencyinduced. osteoporosis, osteoclast formation and RANKL induced signalling
|
|
- Kristopher Summers
- 5 years ago
- Views:
Transcription
1 Dihydroartemisinin, an anti-malaria drug, suppresses estrogen deficiencyinduced osteoporosis, osteoclast formation and RANKL induced signalling pathways Lin Zhou 1, Qian Liu 1, 2, Mingli Yang 1, Tao Wang 2, Jun Yao 1,2, Jianwen Cheng 1,2, Jinbo Yuan 1, Xixi Lin 2, Jinmin Zhao 2, Jennifer Tickner 1, Jiake Xu 1,2 1 School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, Western Australia, 6009, Australia 2 Research Centre for Regenerative Medicine and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China, Correspondence to: Jiake Xu jiake.xu@uwa.edu.au Running title: Dihydroartemisinininhibitsosteolysis Keywords: Dihydroartemisinin, Osteoclast, RANKL, bone resorption, Osteolysis
2 Abstract Osteoporosis is an osteolytic disease which features enhanced osteoclast formation and bone resorption. Identification of agents that can inhibit osteoclast formation and function is important for the treatment of osteoporosis. Dihydroartemisinin is a natural compound used to treat malaria but its role in osteoporosis in not known. Here, we found that dihydroartemisinin can suppresses RANKL-induced osteoclastogenesis and bone resorption in a dose dependent manner. Dihydroartemisin inhibited the expression of osteoclast marker genes such as cathepsin K, calcitonin receptor, and TRAcP. Furthermore, Dihydroartemisinin inhibited RANKL-induced NF-κB and NFAT activity. In addition, using an in vivo ovariectomized mouse model, we show that dihydroartemisinin is able to reverse the bone loss caused by ovariectomy. Together, this study shows that dihydroartemisinin attenuates bone loss in ovariectomized mice through inhibiting RANKL-induced osteoclast formation and function, indicating that dihydroartemisinin is a potential treatment option against osteolytic bone diseases.
3 INTRODUCTION Bone is a continuously renewing tissue which is formed by mineralization of an organic matrix. Bone formation by osteoblasts and bone resorption by osteoclasts contributes to the balance of bone remodelling. An imbalance between osteoclast and osteoblast formation and function causes many osteopathic diseases, such as osteoporosis and Paget s disease [1, 2]. Osteoporosis is a common age-related degenerative disease which often affects postmenopausal women due to oestrogen deficiency. According to the 2004 US surgeon General s report, it was estimated that women over 50 years old have a 50% risk of fragility fracture during the remainder of their lifetime, while men of same age have a 20% risk of fragility fracture throughout the remainder of their life time[3]. Fractures caused by osteoporosis are associated with significant morbidity and mortality, and place a large economic burden on society [4]. The functional role of the osteoclast is to resorb bone through secreting acid and proteases to dissolve the organic and mineral components of bone. Receptor activator of nuclear factor kappa-b ligand (RANKL), also called osteoprotegerin ligand (OPGL), TNF-related activation-induced cytokine (TRANCE), and osteoclast differentiation factor (ODF), is a critical cytokine for the formation and activation of osteoclasts [5-7]. The interaction between RANKL and its receptor RANK activates several transcription factors, such as NF-κB, AKT, Activator Protein 1(AP-1), Mitogen Activated Protein kinase (MAPK) and Nuclear Factor of Activated T-cell cytoplasmic 1(NFATc1). Activation of these downstream factors triggers the expression of genes governing osteoclast differentiation and function, including TRACP, Cathepsin K, Matrix Metalloproteinase 9 (MMP-9), and calcitonin receptor (CTR) ultimately resulting in the production of mature multinucleated osteoclasts [8-10]. RANKL is now recognised as an attractive target for the treatment of osteoporosis, as inhibition of RANKL
4 using antibodies, peptides and natural compounds could prevent osteoclast formation and function. This study aims to determine the effect of several natural compounds on inhibiting RANKL induced osteoclast formation and function. Artemisinin is an effective drug for treating malaria. It belongs to the family of sesquiterpene lactones, which are produced by an Artemisia annua plant[11]. Dihydroartemisinin (DHA) is a water-soluble semi-synthetic derivative of artemisinin [12, 13] and it is commercially combined with piperaquine as an effective therapy for malaria [14] with few side effects [15]. DHA has also been found to have the inhibitory effects on cancer cells mainly through modulating the NF-κB pathway [16-19]. However, the effect of DHA on osteoclast formation and osteoporosis is not known. In this study, we examine the role of DHA in osteoporosis in vivo using an ovariectomized (OVX) mouse model, and elucidate its cellular and molecular mechanism of action. We demonstrate that DHA has a protective effect in an oestrogen deficiency-induced osteoporosis mouse model. Furthermore, we found that DHA inhibits the formation and function of osteoclasts via inhibition of the NF-κB and NFAT pathways. As DHA is already used for treatment of malaria and has anti-tumour activity, our study further indicates that DHA could be beneficial for the treatment of osteolytic bone conditions, such as cancer or inflammation-induced osteolysis.
5 METHODS Materials and Reagents DHA was purchased from Chengdu Must Bio-Technology Co., Ltd (Chengdu, Sichuan Province, China), and dissolved in dimethyl sulfoxide (DMSO). Alpha modified Eagles Medium (α-mem) and fetal bovine serum (FBS) were obtained from TRACE (Sydney, Australia). Anti-P-ERK and anti-iκbα antibodies were purchased from Santa Cruz Biotechnology (California, USA), anti-nfatc1 antibody was purchased from BD Bioscience (America) and V-ATPase-d2 was generated as previously described [20]. Mouse anti-β-actin (catalog number: JLA20) was purchased from Developmental Studies Hybridoma Bank (DSHB) (Iowa, IA, USA). The luciferase assay system and MTS assay kit were purchased from Promega (Sydney, Australia). Recombinant GST-rRANKL protein was produced according to a previous paper [21] and recombinant macrophage colony stimulating factor (M-CSF) was used as previously described [22]. In vitro osteoclastogenesis assay Freshly isolated bone marrow macrophages (BMM) from C57BL/6 mice were cultured in T75 flasks in α-mem containing M-CSF. When confluent, BMMs were seeded into 96 well plates at 1x10 6 cells per well with α-mem and M-CSF overnight. The next day, BMMs were stimulated with 50 ng/ml RANKL and in the presence of DHA for every two days until osteoclasts formed. The plate was then fixed with 2.5% glutaraldehyde in phosphate-buffered saline (PBS) for 10 minutes, and stained for tartrate-resistant acidic phosphatase activity (TRAcP). TRAcP positive multinucleated cells with three or more nuclei were scored as osteoclast-like (OCL) cells.
6 In vitro osteoblast differentiation and mineralization For osteoblastogenesis assays, osteoblast precursors from adult calvaria or long bones were obtained as outgrowth from collagenase-treated bone pieces as described previously [23]. The cells were plated into culture dishes at a cell density of cells/ml in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated FBS, 2mM L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin (complete DMEM). When confluent osteogenic media (complete DMEM, 10 nm dexamethasone, 10 mm β-glycerophosphate, and 50 µg/ml ascorbate) was added and cells cultured for 7 days (alkaline phosphatase assay) or 21 days (mineralisation). Alkaline phosphatase staining was performed using the Leukocyte alkaline phosphatase staining kit (Sigma, Castle Hill, Australia). Mineralisation was observed following fixation and staining with 1% alizarin red [24]. ImageJ software was used to measure the mineralized area [25]. MTS assay for cell proliferation and viability MTS assay was used to determine the effects of compounds on BMM cells using a commercially available MTS assay kit (Promega, Sydney, Australia). BMMs were seeded on 96-well plates at 6x10 3 cells per well and incubated overnight. Varying concentrations of DHA were then added to BMMs and the cells were incubated with the compounds for 48 hours. MTS/PMS mixture was then added to each well for two hours according to manufacturer s instructions. The absorbance of MTS was measured by spectrophotometric absorbance at 490 nm using an ELISA plate reader (BMG, Germany). Hydroxyapatite resorption assay BMMs were seeded on to six-well collagen-coated culture plates at a density of 1x10 5 cells per well. Cells were allowed to adhere overnight at 37 C and cells were then stimulated with
7 50ng/ml RANKL and M-CSF until osteoclasts began to form. The cells were gently harvested using cell dissociation solution, counted and equal numbers of multinucleated cells were seeded onto hydroxyapatite-coated plates (Corning, America). DHA was added to the cells after they were seeded onto the hydroxyapatite plate. After 48 hours, half of the wells were fixed and stained for TRAcP activity for osteoclast counting and the remainder of the wells were bleached and dried for hydroxyapatite resorption visualisation using a Nikon microscope and analysed using Image J software. RNA extraction and analysis Freshly isolated BMM cells from C57BL/6 mice were cultured in T75 flasks then seeded in six-well plates at a density of 1x10 5 cells per well. Cells were then stimulated with RANKL and M-CSF in the presence of DHA for 5 days. After osteoclasts were formed, cells were lysed, and total RNA was extracted using Trizol (Life Technologies, Mulgrave, Australia) in accordance with the manufacturer s protocol. For reverse transcription (RT)-PCR, singlestranded cdna was reverse transcribed from 1μg total RNA using reverse transcriptase with an oligo-dt primer. For relative quantitative real-time polymerase chain reaction (PCR), SYBR Green PCR MasterMix was used. The cycling parameters for PCR were set as follows: 94 C for 5 min, followed by 30 cycles of 94 C (40 sec), 60 C, (40 sec); 72 C (40 sec), followed by an elongation step of 5 min at 72 C. PCR reactions used specific primers for detecting and quantifying the following genes: Cathepsin K (forward: 5 - GGGAGAAAAACCTGAAGC-3 ; reverse: 5 - ATTCTGGGGACTCAGAGC-3 ), calcitonin receptor (forward: 5 - TGGTTGAGGTTGTGCCCA-3 ; reverse: 5 - CTCGTGGGTTTGCCTCATC-3 ), TRACP (forward: 5 -TGTGGCCATCTTTATGCT-3 ; reverse:5 -GTCATTTCTTTGGGGCTT-3 ),, and 18s RNA (forward: 5 - ACCATAGATGCCGACT- 3 ; reverse: 5 -TGTCAATCCTGTCCGTGTC-3. qpcr reaction
8 results were read on a ViiA 7Real-time PCR machine (Applied Biosystems, United Kingdom).The comparative 2 -ΔΔCT method was used to calculate the relative expression of each target gene. The mean Ct value of target genes in the experimental group was normalized to the Ct value of 18S to give a ΔCt value, which was further normalized to control samples to obtain ΔΔCt. Three independent cultures were carried out, and all experiments were performed in triplicate. NF-κB and NFAT luciferase assay For NF-κB and NFAT luciferase assay, RAW264.7 cells stably transfected with an NF-κB luciferase reporter construct (3κB-Luc-SV40) (Wang et al., 2003) or an NFAT luciferase reporter construct (van der Kraan et al., 2013) were seeded onto a 48-well plate at the density of 1.5x10 5 or 5x10 4 cells per well. The following day, the cells were treated with DHA only for one hour, followed by stimulation with RANKL for 6 hours (NF-κB luciferase reporter gene assays) or 24 hours (NFAT luciferase reporter gene assays) inthe presence of DHA. Cells were then lysed and centrifuged for 20 minutes at 14000g at 4 C. Luciferase activity was then measured using the Promega luciferase kit and a BMG Polar Star Optima luminescence reader (BMG, Germany). Western blot assays Freshly isolated BMM cells from C57BL/6mice were seeded into six-well plates, and stimulated with RANKL and M-CSF in the presence of DHA. After 5 days, osteoclasts had formed and cells were lysed with RIPA buffer for protein extraction. Protein was separated by SDS-PAGE electrophoresis, and then transferred to a nitrocellulose membrane. The membrane was blocked in a 5% skim milk for 1 hour then probed with specific antibodies, including P-ERK, ERK, IKBα, NFATc1, V-ATPase-d2, and β-actin antibodies. After
9 washing three times with TBST, membranes were incubated with appropriate HRPconjugated secondary antibodies. Finally, the membrane was developed using Enhanced Chemiluminescence (ECL) reagents (Amersham) according to manufacturer s instructions and imaged using an Image quant LAS 4000 (GE Healthcare, Australia). Ovariectomized (OVX) mouse model The animal experiments were approved by the Institutional Animal Ethics Committee of Guangxi Medical University. Eighteen C57BL/6 mice aged 7 weeks old were randomly divided into three groups, which were sham group, OVX group and OVX+DHA (1mg/kg) group. Each group contained 6 mice. OVX group and OVX+DHA group were given an ovariectomy operation, while the sham group were given a sham operation as a control. After the procedure all mice had one week for postoperative recovery. Then the mice in OVX+DHA group were given intraperitoneal injection of DHA at 1mg/kg for every two days. The mice in the sham and OVX group were intraperitoneally injected with 4% DMSO as a control. After 6 weeks, all the mice were sacrificed. Their tibiae were collected and fixed in 10% neutral buffered formalin. Excess soft tissue was removed and the cleaned tibias were prepared for microct analysis by wrapping in tissue soaked in phosphate buffered saline (PBS) and loading into a 2ml Eppendorf tube to maintain position, hydration, and to prevent movement artefacts. Tubes were then immobilised using foam inserts in the bed of a Skyscan 1176 microct instrument (Bruker). Each tibia was then imaged with the following instrument settings: 50kV, 500μA, 0.5mm Al filter, 952ms exposure, pixel size 8.89 μm, 2 frame averaging, 0.4 rotation step through 180. Images were then reconstructed using NRecon software (Bruker) with a constant threshold value. A volume of interest containing the proximal head of the tibia was generated and this volume was loaded into the analysis program CTAn (Bruker). A refined volume of interest was then generated 0.5mm below the
10 growth plate and 1mm in height. The trabecular bone region of interest (ROI) within this volume was manually defined and bone parameters within this ROI were determined using a constant threshold for binarisation of the trabecular bone. Following microct analysis bones were decalcified and embedded into paraffin blocks for sectioning and staining. Sequential 5μm thick sections were prepared and stained using haematoxylin and eosin, or for TRACP activity. Sections were scanned using Aperio Scanscope, and bone histomorphometric analyses were performed using BIOQUANT OSTEO software (Nashville, USA). Statistical analysis All values are presented as the mean ± standard deviation (SD) of the values obtained from three or more experiments. Statistical significance was determined by Student s t test. A P value of less than 0.05 was considered to be significant. RESULTS DHA inhibits RANKL induced osteoclastogenesis In order to determine the effect of DHA on the formation of osteoclasts, osteoclastogenesis assays were performed. BMMs were seeded in 96 well plate at 6x10 3 per well. After overnight incubation, DHA was added to the plate every two days until osteoclasts were formed. The results showed that DHA inhibited RANKL induced osteoclastogenesis in a dose-dependent manner. DHA significantly inhibited osteoclast formation at doses greater than 0.5 µm (Fig.1B. C). To determine any cytotoxic effects of DHA on BMM, a cell survival assay was performed. Our results showed that concentrations of DHA that were effective at inhibiting osteoclastogenesis (0.5µM and 1µM) did not have any cytotoxic effects on BMM (Fig.1D). Similar results were also found when BMM were treated with artemisinin; however, the effect of artemisinin was weaker than that of DHA. The minimum
11 dose of artemisinin which significantly inhibited osteoclastogenesis was 1µM (Supplementary Fig. 1). We also assessed the effect of DHA on osteoblast formation and mineralization using in vitro osteoblastogenesis assays. We found no effect of DHA on osteoblast alkaline phosphatase staining, and no changes in mineralization in osteoblast cultures (Supplementary Fig. 2). Thus, for the subsequent studies, DHA was chosen as a prototype to further examine its mechanism of action in osteoclastogenesis and therapeutic potential in vivo. DHA suppresses RANKL induced osteoclast function Hydroxyapatite-coated plates were used to test the effect of 48 hour treatment with DHA on mature osteoclast resorptive function. The percentage of resorbed area per osteoclast was reduced in the presence of DHA. The number of osteoclasts was also reduced by DHA but to a lesser degree relative to resorbing area (Fig.2). These results suggested that DHA restrains the bone resorbing activity of osteoclasts. DHA inhibits RANKL-induced gene expression Real time PCR was used to assess the effect of DHA on RANKL-induced gene expression levels during osteoclastogenesis. The results showed that the expression of the osteoclast marker genes cathepsin K, calcitonin receptor and TRAcP were significantly and dosedependently inhibited by DHA at day 5 of culture. These results were consistent with osteoclast formation and activity assays (Fig.3). DHA suppresses RANKL-induced NF-κB activation and ERK phosphorylation In order to further explore the mechanism of inhibition by DHA on osteoclast differentiation and activity, NF-κB luciferase reporter assay and IκBα degradation analysis was performed. RAW264.7 cells stably transfected with an NF-κB luciferase reporter construct were pre-
12 treated with different concentrations of DHA up to 5μM for 1 hour, then stimulated with 50ng/ml RANKL for another 6 hours. For Western blot assay, BMMs pre-treated for 1 hour with 1μM DHA were stimulated with RANKL for 0, 5, 10, 20, 30, 60 minutes. The results showed that DHA significantly inhibited NF-κB activation in a dose-dependent manner from the concentration of 0.5 µm (Fig. 4A). The results of Western blot analysis showed that DHA at 1 µm significantly inhibited IκBα degradation relative to no treatment at 10 minutes poststimulation (Fig. 4B. C), and also strongly inhibited the RANKL-induced phosphorylation of ERK relative to total ERK (Fig. 4B. C). DHA suppresses RANKL-induced NFAT activation To examine the effect of DHA on NFAT activation, NFAT luciferase reporter assay was performed. Similarly to the NF-κB luciferase reporter assay, RAW264.7 cells stably transfected with an NFAT luciferase reporter construct were first pre-treated with different concentrations of DHA up to 5 μm for 1 hour, followed by RANKL (50ng/ml) stimulation for another 24 hours. Cells were then harvested for luciferase activity measurement. The results showed that NFAT activation was significantly reduced by DHA at concentrations greater than 0.5 µm. DHA produced a greater than ten-fold reduction in NFAT activation at the concentrations of 2.5 and 5 µm (Fig. 5A). NFATc1 is a key transcription factor regulating the differentiation of osteoclasts, and autoamplifies its own transcription during osteoclastogenesis [26]. To assess NFATc1 protein levels, Western blot assay was performed with BMMs stimulated by RANKL (50ng/ml) for 0, 1, 3, and 5 days in the presence or absence of DHA. Protein levels of NFATc1 and V- ATPase-d2 were significantly reduced by DHA treatment consistent with the observed
13 reduction in osteoclast formation (Fig. 5B. C). The maximum reduction of V-ATPase-d2 was at 5 days while the maximum reduction of NFATc1 was at 3 days (Fig. 5B. C). DHA inhibits ovariectomy-induced bone loss To determine the effect of DHA on ovariectomy-induced bone loss, mice were either sham operated, or ovariectomized (OVX) and were then treated with either DHA at a concentration of 1mg/kg every 2 days, or DMSO only control, by intraperitoneal injection for 6 weeks postsurgery. The tibias were then collected for micro-ct analysis. Our results showed that DHA treatment protected the mice from bone loss associated with OVX, as shown by increased BV/TV in treated mice relative to the OVX mice without treatment (Fig.6). Furthermore, trabecular separation (Tb.Sp) was significantly reduced in the OVX + DHA group when compared with OVX control group (Fig.6). These results indicated that DHA protected against ovariectomy-induced bone loss. To further confirm the effect of DHA on ovariectomy-induced bone loss, histomorphometric analysis was also performed. Consistent with the microct results, there was an increase in BV/TV in the OVX + DHA group when compared with the OVX group (Fig.7). In addition, osteoclast surface/bone surface (Oc.S/BS) and osteoclast number/bone surface (N.Oc/Bs) were decreased in DHA treated OVX mice as compared with OVX group. Consistent with our in vitro results the osteoblast number/bone surface (N.Oc/Bs) was not significantly changed following DHA treatment versus the OVX group (Fig.7). This result suggested that DHA protected against ovariectomy-induced bone loss through inhibiting osteoclast number and activity.
14 DISCUSSION Artemisinin (Qinghaosu) is a natural compound extracted from Artemisia annua, which has been used to treat malaria in China for more than two thousand years. DHA is a semisynthetic derivative of artemisinin and is used in combination with piperaquine for the treatment of malaria patients, which is an effective remedy for malaria. Recently, DHA was also found to inhibit cancer cells, such as breast cancer cells [27, 28] and lung cancer cells [29, 30]. Furthermore, DHA was able to inhibit tumor angiogenesis [31]. DHA was found to exert these inhibitory effects on cancer cells through regulating the NF-κB pathway [16-19]. In this study, we have explored the effect of DHA on osteoclast formation and activity, and in an OVX-induced bone loss mouse model, as we found that DHA is more effective than artemisinin at inhibiting osteoclast formation. Our results showed that DHA inhibited RANKL induced osteoclastogenesis at concentrations of 0.5 µm and higher without affecting the viability of BMM; however, mature osteoclast survival and function was affected at these doses, resulting in significant reductions in osteoclast activity. We also found that osteoblast formation and function was not affected by DHA treatment. These findings suggest that DHA might represent an efficient drug prototype for the treatment of osteoclast-mediated osteolysis. In concordance with its inhibitory effect on osteoclastogenesis, DHA was found to suppress NF-κB in a luciferase reporter gene assay and significantly inhibit osteoclast marker gene expression. The RANKL induced NF-κB pathway is the major signal pathway activated during osteoclastogenesis [32]. The interaction between RANK and RANKL results in the rapid degradation of IκB by the proteasome and subsequent release of NF-κB, which then translocates from the cytoplasm to the nucleus. It then initiates transcription of osteoclast
15 specific genes necessary for osteoclast differentiation and function [33-36]. Our results have demonstrated an inhibitory effect of DHA on NF-κB activation through modulating IκBα protein levels, degradation, and downstream gene expression, indicating that DHA is inhibiting the NF-κB signaling pathway similar to its known mechanism of action in other cell types [16-19, 37]. DHA was also able to reduce NFAT activity in a luciferase reporter gene assay, and the expression of NFAT by Western blot assay. RANKL-induced NFATc1 is another important signaling pathway leading to osteoclast formation [38, 39]. The NFAT signalling cascade activates phospholipase C γ (PLCγ) and leads to the release of intracellular Ca 2+, resulting in the activation of calcineurin and transcription and auto amplification of NFATc1 [40]. Our studies are the first to identify NFATc1 regulation by DHA, although it is interesting to note that the mechanism of DHA action in Plasmodium falciparum is to disrupt SERCA pumps resulting in Ca 2+ disturbances [41, 42]. Although it has been reported that artemisinin does not inhibit mammalian SERCA isoforms, DHA has not been assessed. The importance of Ca 2+ signaling in osteoclast NFAT activation may explain the sensitivity of osteoclasts to DHA. Similar inhibitory effects have been noted on osteoclast survival and differentiation using other SERCA inhibitors such as thapsigargin [43]. NFAT signalling is also downstream of NF-κB, thus the suppression of NFATc1 by DHA could potentially result from the suppression of NF-κB signaling [44]. Thus, the inhibitory effect on NFATc1 by DHA could be due to indirect inhibition of NFAT through NF-κB. Our results showed that downstream targets of NFAT activation [20], including V-ATPase-d2 that is important for osteoclast fusion [45, 46], are inhibited by DHA suggesting that suppression
16 of NFATc1 is an important component of the mechanism of DHA inhibition of RANKLinduced osteoclastogenesis. In addition, our western blot results showed that DHA inhibits RANKL-induced ERK phosphorylation. The binding of RANKL to RANK also activates ERK, which is a mitogen activated protein kinase (MAPK) [47] that is downstream of tumor necrosis factor receptorassociated factor 6 (TRAF6) [48]. Inhibition of ERK phosphorylation has been observed in HUVEC cells treated with DHA [49], and ERK is crucial for the survival of osteoclasts [50]. Hence the observed reduction in ERK phosphorylation in the presence of DHA may account for the reduced survival that we observed in mature osteoclast cultures. Thus, the effect of DHA on osteoclasts is multifactorial via the inhibition of multiple signaling pathways including NF-κB, ERK and NFATc1 signaling pathways. Based on the in vitro results, an OVX animal model was used for the evaluation of the function of DHA in osteoporosis. Our results showed that OVX mice were protected from bone loss by DHA treatment via inhibiting osteoclast formation and function, with no toxicity in mice. These preclinical experimental results are consistent with the in vitro results, and suggest that in addition to its anti-malaria [14] and anti-cancer effects [16-19], DHA has a new potential therapeutic effect against osteoporosis and other lytic bone diseases.
17 Acknowledgements The authors acknowledge the facilities, and the scientific and technical assistance of the National Imaging Facility at the Centre for Microscopy, Characterisation & Analysis, The University of Western Australia, a facility funded by the University, State and Commonwealth Governments. This study was supported in part by the National Health and Medical Research Council of Australia. This study was also supported by a grant from the National Natural Science Foundation of China (NSFC) (No: ), Arthritis foundation of Australia, The University of Western Australia (UWA) Research Collaboration Awards (2014). It is supported by RAINE research fellowship to Dr. Jennifer Tickner and a PhD scholarship from the Chinese Scholarship Council (Lin Zhou).This project is also sponsored in part by Co-innovation Centre for Bio-Medicine, Guangxi Colleges and Universities Key Laboratory of Regenerative Medicine and Innovation Team of Tissue Repair and Reconstruction to Dr. Jianwen Cheng, Qian Liu, Jun Yao and Tao Wong who were Visiting Scholars to the University of Western Australia ( ). Prof. Jiake Xu and Dr. Lin Zhou made mutual collaborative visits to Guangxi Medical University in 2014.
18 References 1. Goltzman, D., Osteolysis and cancer. J Clin Invest, (10): p Redlich, K., et al., Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum, (3): p in Bone Health and Osteoporosis: A Report of the Surgeon General2004: Rockville (MD). 4. Harvey, N., E. Dennison, and C. Cooper, Osteoporosis: impact on health and economics. Nat Rev Rheumatol, (2): p Lacey, D.L., et al., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, (2): p Kong, Y.Y., et al., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, (6717): p Yasuda, H., et al., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A, (7): p Takayanagi, H., Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol, (12): p Zhu, L.L., et al., RANK-L induces the expression of NFATc1, but not of NFkappaB subunits during osteoclast formation. Biochem Biophys Res Commun, (1): p Zou, W. and S.L. Teitelbaum, Integrins, growth factors, and the osteoclast cytoskeleton. Ann N Y Acad Sci, : p Klayman, D.L., Qinghaosu (artemisinin): an antimalarial drug from China. Science, (4703): p Lin, A.J., D.L. Klayman, and W.K. Milhous, Antimalarial activity of new water-soluble dihydroartemisinin derivatives. J Med Chem, (11): p Tu, Y., The development of new antimalarial drugs: qinghaosu and dihydro-qinghaosu. Chin Med J (Engl), (11): p Ashley, E.A., et al., A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis, (4): p Gordi, T. and E.I. Lepist, Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett, (2): p Ji, Y., et al., Anti-tumor effects of dihydroartemisinin on human osteosarcoma. Mol Cell Biochem, (1-2): p Lee, J., et al., Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-kappaB modulation. J Cancer Res Clin Oncol, (12): p Hwang, Y.P., et al., Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. Biochem Pharmacol, (12): p Chen, H., et al., Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappab. J Cancer Res Clin Oncol, (6): p Feng, H., et al., Myocyte enhancer factor 2 and microphthalmia-associated transcription factor cooperate with NFATc1 to transactivate the V-ATPase d2 promoter during RANKLinduced osteoclastogenesis. J Biol Chem, (21): p Xu, J., et al., Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J Bone Miner Res, (11): p
19 22. Liu, Q., et al., SC-514, a selective inhibitor of IKKbeta attenuates RANKL-induced osteoclastogenesis and NF-kappaB activation. Biochem Pharmacol, (12): p Bakker, A.D. and J. Klein-Nulend, Osteoblast isolation from murine calvaria and long bones. Methods Mol Biol, : p Chim, S.M., et al., EGFL6 promotes endothelial cell migration and angiogenesis through the activation of extracellular signal-regulated kinase. The Journal of biological chemistry, (25): p Schneider, C.A., W.S. Rasband, and K.W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis. Nat Methods, (7): p Takayanagi, H., The role of NFAT in osteoclast formation. Ann N Y Acad Sci, : p Ericsson, T., et al., Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol, (12): p Singh, N.P. and H. Lai, Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci, (1): p Liu, L.K., et al., Targeted efficacy of dihydroartemisinin for translationally controlled protein expression in a lung cancer model. Asian Pac J Cancer Prev, (6): p Zuo, Z.J., et al., [Effect of dihydroartemisinin combined irradiation on the apoptosis of human lung cancer GLC-82 cells and its mechanism study]. Zhongguo Zhong Xi Yi Jie He Za Zhi, (10): p Jung, M., et al., Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane. Bioorg Med Chem Lett, (5): p Xu, J., et al., NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev, (1): p Brown, K.D., E. Claudio, and U. Siebenlist, The roles of the classical and alternative nuclear factor-kappab pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther, (4): p Mercurio, F. and A.M. Manning, Multiple signals converging on NF-kappaB. Curr Opin Cell Biol, (2): p Mercurio, F. and A.M. Manning, NF-kappaB as a primary regulator of the stress response. Oncogene, (45): p Dixit, V. and T.W. Mak, NF-kappaB signaling. Many roads lead to madrid. Cell, (5): p Dong, F., et al., Dihydroartemisinin targets VEGFR2 via the NF-kappaB pathway in endothelial cells to inhibit angiogenesis. Cancer biology & therapy, (11): p Hirotani, H., et al., The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem, (14): p Matsuo, K., et al., Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-fos. J Biol Chem, (25): p Kular, J., et al., An overview of the regulation of bone remodelling at the cellular level. Clin Biochem, (12): p Krishna, S., et al., Artemisinins: their growing importance in medicine. Trends in pharmacological sciences, (10): p Eckstein-Ludwig, U., et al., Artemisinins target the SERCA of Plasmodium falciparum. Nature, (6951): p Yip, K.H., et al., Thapsigargin modulates osteoclastogenesis through the regulation of RANKLinduced signaling pathways and reactive oxygen species production. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, (8): p
20 44. Takatsuna, H., et al., Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res, (4): p Kim, K., et al., NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol, (1): p Lee, S.H., et al., v-atpase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med, (12): p Nakamura, H., et al., Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res, (7): p Kobayashi, N., et al., Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J, (6): p Dong, F., et al., Dihydroartemisinin inhibits endothelial cell proliferation through the suppression of the ERK signaling pathway. International journal of molecular medicine, (5): p Miyazaki, T., et al., Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol, (2): p
21 Figure legends Fig.1. DHA inhibits RANKL-induced osteoclastogenesis. (A) The molecular structure of Dihydroartemisinin (DHA). (B) Representative images of osteoclast cultures treated with varying concentrations of DHA for 5 days. Mag = 100X, scale bar = 100μm (C) Quantification of TRAcP positive, multinucleated cells following treatment with varying concentrations of DHA. n=3 *p <0.05, **p<0.01, ***p<0.001 relative to DHA-untreated controls. (D) Proliferation of M-CSF stimulated BMM cells following incubation with DHA at different concentrations for 48 hours as measured by MTS assay. n=3. *p <0.05, **p<0.01, ***p<0.001 relative to DHA-untreated controls. Fig.2. DHA suppresses hydroxyapatite resorption. (A) Representative images of TRAP staining and osteoclastic resorption on hydroxyapatite coated surfaces (scale bars = 500 µm). (B) Quantitative analysis of the number of TRAP positive multinucleated cells. n=3 *p<0.05, **p<0.01, ***p<0.001 relative to DHA-untreated controls. (C) Quantitative analysis of the percentage of the area of hydroxyapatite surface resorbed per osteoclast. n=3. *p<0.05, **p<0.01, ***p<0.001 relative to DHA-untreated controls. Fig.3. DHA suppresses RANKL-induced gene expression during osteoclastogenesis. Real time-pcr analysis was performed on RNA extracted from cells stimulated for 5 days with RANKL and varying concentrations of DHA. Gene expression of osteoclast marker genes Cathepsin K, Calcitonin Receptor and TRAcP was normalized to 18S RNA and then compared to RANKL-only control samples to obtain the relative fold change. n=3. *p<0.05, **p<0.01, ***p<0.001 relative to RANKL-treated, DHA-untreated controls. Fig.4. DHA inhibits RANKL-stimulated NF-κB activity and IκB-α degradation. (A) RAW264.7 cells stably transfected with an NF-κB luciferase reporter construct were first treated with DHA for 1 hour, then stimulated with RANKL for 6 hours. The luciferase activity was then measured using a BMG Polar Star Optima luminescence reader. n=3. *p<0.05, **p<0.01, ***p<0.001 relative to RANKL-treated, DHA-untreated controls. (B) BMM cells pretreated with DHA (1µM) for 1 h, were then stimulated with RANKL (100 ng/ml) for 0, 5, 10, 20, 30 and 60 mins. Protein was then extracted for Western Blot analysis using antibodies against IκB-α, β-actin, P-ERK1/2 and total ERK1/2. (C) The ratios of the density of IκB-α bands relative to β-actin bands and P-ERK1/2 bands relative to total ERK1/2 bands were then determined using Image J. n=3. *p<0.05, **p<0.01, ***p<0.001 relative to RANKL-treated, DHA-untreated controls. Fig.5. DHA inhibits RANKL-stimulated NFAT activity and the expression of NFATc1 and V-ATPase-d2. (A) RAW264.7 cells stably transfected with an NFAT luciferase reporter
22 construct were first treated with DHA for 1 hour, then stimulated with RANKL for 24 hours. The luciferase activity was then measured by a BMG Polar Star Optima luminescence reader. n=3. *p<0.05, **p<0.01, ***p<0.001 relative to RANKL-treated, DHA-untreated controls. (B) BMM cells were pretreated with DHA (1µM) for 1 h, then stimulated with RANKL (100 ng/ml) for 0, 1, 3, 5 days. Protein was then extracted for Western Blot analysis using antibodies against NFATc1, V-ATPase-d2 and β-actin antibodies. (C) The ratio of the density of NFATc1 bands relative to β-actin bands, and V-ATPase-d2 bands relative to β-actin bands was then determined using Image J. n=3. *p<0.05 relative to RANKL-treated, DHAuntreated controls. Fig.6. DHA reduces ovariectomy-induced bone loss. (A) Representative 3D reconstructions of trabecular bone from the tibia of sham, OVX and OVX treated with 1mg/kg DHA mice showing the protective effect of DHA treatment following OVX. (B) Quantitative analysis of bone volume/total volume (BV/TV), trabecular separation (Tb.Sp), trabecular number (Tb.N), and trabecular thickness (Tb.Th). n=8. *p<0.05, **p<0.01, ***p<0.001 relative to OVX untreated controls. Fig.7. DHA protects against ovariectomy-induced bone loss via inhibiting osteoclast activity. (A) Representative images of decalcified bone stained with H&E and TRAP from sham, OVX and OVX treated with 1mg/kg DHA mice. Scale bar =500µM. (B) Quantitative analysis of bone volume/total volume (BV/TV), osteoclast surface/bone surface (Oc.S/BS), osteoclast number/bone surface (N.Oc/BS) and osteoblast number/bone surface (N.Ob/BS). n=3. *p<0.05 and **p<0.01 relative to OVX untreated controls. Supplementary Fig.1. Artemisinin inhibits RANKL-induced osteoclastogenesis. (A) The molecular structure of artemisinin. (B) Representative images of osteoclast cultures treated with varying concentrations of artemisinin for 5 days. Mag = 100X, scale bar = 100μm (C) Quantification of the effect of artemisinin at different concentrations by counting TRAcP+ multinucleated cells (Nuclei 3) as osteoclasts. (C) Quantification of TRAcP positive, multinucleated cells following treatment with varying concentrations of artemisinin. n=3. **p<0.01, ***p<0.001 relative to artemisinin-untreated controls. Supplementary Fig.2. DHA does not affect osteoblast mineralisation and alkaline phosphatase activity. Cells derived from calvarial bone outgrowth were cultured in osteogenic medium and stained for alkaline phosphatase (ALP) activity and mineralization. (A) Low power image showing ALP staining of calvarial cells. (B) Low power scanned image of tissue culture plate containing calvarial cells treated with DHA and stained with alizarin red. (C) High magnification image of mineralised nodules formed in the presence and
23 absence of DHA (Mag = 40X). (D) Quantitative analysis of area of ALP staining relative to untreated cells. (E) Quantitative analysis of mineralization area following treatment with DHA relative to untreated cells.
Supplementary data Supplementary Figure 1 Supplementary Figure 2
Supplementary data Supplementary Figure 1 SPHK1 sirna increases RANKL-induced osteoclastogenesis in RAW264.7 cell culture. (A) RAW264.7 cells were transfected with oligocassettes containing SPHK1 sirna
More informationInhibition of andrographolide in RAW murine macrophage osteoclastogenesis by downregulating the nuclear factor-kappab signaling pathway
Inhibition of andrographolide in RAW 264.7 murine macrophage osteoclastogenesis by downregulating the nuclear factor-kappab signaling pathway Y.Q. Ren 1 and Y.B. Zhou 2 1 Department of Orthopedics 1, Yuyao
More informationSiglec-15 Is A Potential Therapeutic Target For Postmenopausal Osteoporosis
Siglec-15 Is A Potential Therapeutic Target For Postmenopausal Osteoporosis Yusuke Kameda, Masahiko Takahata, Tomohiro Shimizu, Hiroki Hamano, Norimasa Iwasaki. Department of Orthopedic Surgery, Hokkaido
More informationGeneral Laboratory methods Plasma analysis: Gene Expression Analysis: Immunoblot analysis: Immunohistochemistry:
General Laboratory methods Plasma analysis: Plasma insulin (Mercodia, Sweden), leptin (duoset, R&D Systems Europe, Abingdon, United Kingdom), IL-6, TNFα and adiponectin levels (Quantikine kits, R&D Systems
More informationSerum Amyloid A3 Gene Expression in Adipocytes is an Indicator. of the Interaction with Macrophages
Serum Amyloid A3 Gene Expression in Adipocytes is an Indicator of the Interaction with Macrophages Yohei Sanada, Takafumi Yamamoto, Rika Satake, Akiko Yamashita, Sumire Kanai, Norihisa Kato, Fons AJ van
More informationMutation in Osteoactivin Enhances RANKL-Mediated Signaling, Promoting Osteoclast Differentiation, Survival and Inhibiting Bone Resorption
Mutation in Osteoactivin Enhances RANKL-Mediated Signaling, Promoting Osteoclast Differentiation, Survival and Inhibiting Bone Resorption Samir Abdelmagid, MD, PhD, Fouad Moussa, BS, Sondag Gregory, MS,
More informationIntracellular MHC class II molecules promote TLR-triggered innate. immune responses by maintaining Btk activation
Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining Btk activation Xingguang Liu, Zhenzhen Zhan, Dong Li, Li Xu, Feng Ma, Peng Zhang, Hangping Yao and Xuetao
More informationData Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538
Data Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538 Background: TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory
More informationSUPPLEMENTAL MATERIAL. Supplementary Methods
SUPPLEMENTAL MATERIAL Supplementary Methods Culture of cardiomyocytes, fibroblasts and cardiac microvascular endothelial cells The isolation and culturing of neonatal rat ventricular cardiomyocytes was
More informationsilent epidemic,. (WHO),
Tel: 02-740-8686; E-mail: hhbkim@snu.ac.kr silent epidemic,. (WHO),. 5 3, 1. 50 70. 50%, 25%, 20% (12~35%). 2.8% 0.7% 4. ( ). bone remodeling (osteoblast), (osteoclast),.. 3~4.. 70% (osteocyte) (bone lining
More informationSupplemental figures and figure legends (90517-INS-RG-RV-2) Supplemental Figure 1.
Supplemental figures and figure legends (957-INS-RG-RV-) Supplemental Figure. A B.5.5 Interaction p=.89 Model p
More informationOsteoclast Activity Assay Substrate
Osteoclast Activity Assay Substrate For Research Use Only OSCOTECT INC. #3201 Trade Tower Samsung-dong 159, Kangnam-ku Seoul 135-729, Korea Tel: +82-2-6000-7666 / Fax: +82-2-6000-7667 customer@oscotec.com
More informationMicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells Margaret S Ebert, Joel R Neilson & Phillip A Sharp Supplementary figures and text: Supplementary Figure 1. Effect of sponges on
More informationFructose Upregulates FGF23 Expression In MC3T3 Pre-osteoblasts
Fructose Upregulates FGF23 Expression In MC3T3 Pre-osteoblasts Edek A. Williams, B.S.E., Veronique Douard, Ph.D., Joseph M. Lomuti, B.S., Ronaldo Ferraris, Ph.D., J. C. Fritton, Ph.D.. Rutgers University,
More informationA549 and A549-fLuc cells were maintained in high glucose Dulbecco modified
Cell culture and animal model A549 and A549-fLuc cells were maintained in high glucose Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum at 37 C in humidified atmosphere containing
More informationIL-17 in health and disease. March 2014 PSO13-C051n
IL-17 in health and disease March 2014 PSO13-C051n Originally Researchers Suggested That IL-12 and IL-4 drove Th Cell Differentiation Naïve CD4 + T cell Question: Which of these cell types is responsible
More informationThe Regulation of Cathepsin K Gene Expression
The Regulation of Cathepsin K Gene Expression BRUCE R. TROEN Geriatrics Research, Education, and Clinical Center & Research Service, Miami Veterans Affairs Medical Center, and Geriatrics Institute, Department
More informationTITLE: Inhibition of Prostate Cancer Skeletal Metastases by Targeting Cathepsin K
AD Award Number: W81XWH-07-1-0028 TITLE: Inhibition of Prostate Cancer Skeletal Metastases by Targeting Cathepsin K PRINCIPAL INVESTIGATOR: Jian Zhang, M.D., Ph.D. CONTRACTING ORGANIZATION: University
More informationSupplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk
Supplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk -/- mice were stained for expression of CD4 and CD8.
More informationp47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO
Supplementary Information p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO Yuri Shibata, Masaaki Oyama, Hiroko Kozuka-Hata, Xiao Han, Yuetsu Tanaka,
More informationDoctoral Degree Program in Marine Biotechnology, College of Marine Sciences, Doctoral Degree Program in Marine Biotechnology, Academia Sinica, Taipei,
Cyclooxygenase 2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents Chun-Kuang Lin 1,2, Chin-Kai Tseng 3,4, Yu-Hsuan Wu 3,4, Chih-Chuang Liaw 1,5, Chun-
More informationMTC-TT and TPC-1 cell lines were cultured in RPMI medium (Gibco, Breda, The Netherlands)
Supplemental data Materials and Methods Cell culture MTC-TT and TPC-1 cell lines were cultured in RPMI medium (Gibco, Breda, The Netherlands) supplemented with 15% or 10% (for TPC-1) fetal bovine serum
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION FOR Liver X Receptor α mediates hepatic triglyceride accumulation through upregulation of G0/G1 Switch Gene 2 (G0S2) expression I: SUPPLEMENTARY METHODS II: SUPPLEMENTARY FIGURES
More informationKeiji Kobayashi, Hidetoshi Nojiri, Yoshitomo Saita, Daichi Morikawa, Yusuke Ozawa, Kenji
Supplementary Information Mitochondrial superoxide in osteocytes perturbs canalicular networks in the setting of age-related osteoporosis Keiji Kobayashi, Hidetoshi Nojiri, Yoshitomo Saita, Daichi Morikawa,
More informationEssential Medium, containing 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. Huvec were cultured in
Supplemental data Methods Cell culture media formulations A-431 and U-87 MG cells were maintained in Dulbecco s Modified Eagle s Medium. FaDu cells were cultured in Eagle's Minimum Essential Medium, containing
More informationSupplementary Material for
Supplementary Material for Parathyroid Hormone Signaling through Low-density-lipoprotein-related Protein 6 Mei Wan, Chaozhe Yang, Jun Li, Xiangwei Wu, Hongling Yuan, Hairong Ma, Xi He, Shuyi Nie, Chenbei
More informationCellular Physiology and Biochemistry
Original Paper 2015 The Author(s). 2015 Published The Author(s) by S. Karger AG, Basel Published online: November 27, 2015 www.karger.com/cpb Published by S. Karger AG, Basel 2194 1421-9778/15/0376-2194$39.50/0
More informationSUPPLEMENTARY INFORMATION
1. Supplementary Figures and Legends Supplementary Fig. 1. S1P-mediated transcriptional regulation of integrins expressed in OP/monocytoid cells. Real-time quantitative PCR analyses of mrna for two integrins,
More informationOsteoclast Culture Kit
K-ASSAY KAMIYA BIOMEDICAL COMPANY Osteoclast Culture Kit For the culture of Osteoclasts from precursor cells. Cat. No.: CC-107 Rat Osteoclast Precursor Cells, V-1 CC-109 Mouse Osteoclast Precursor Cells,
More informationData Sheet. NFAT Reporter (Luc) Jurkat Cell line Catalog #: 60621
Data Sheet NFAT Reporter (Luc) Jurkat Cell line Catalog #: 60621 Background The nuclear factor of activator T cells (NFAT) family of transcription factors plays an important role in immune response. T
More informationLi et al. Journal of Experimental & Clinical Cancer Research (2018) 37:108
Li et al. Journal of Experimental & Clinical Cancer Research (2018) 37:108 https://doi.org/10.1186/s13046-018-0774-7 CORRECTION Correction to: Novel smac mimetic APG- 1387 elicits ovarian cancer cell killing
More informationNotch Signaling Pathway Notch CSL Reporter HEK293 Cell line Catalog #: 60652
Notch Signaling Pathway Notch CSL Reporter HEK293 Cell line Catalog #: 60652 Background The Notch signaling pathway controls cell fate decisions in vertebrate and invertebrate tissues. Notch signaling
More information(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-
1 Supplemental Figure Legends Figure S1. Mammary tumors of ErbB2 KI mice with 14-3-3σ ablation have elevated ErbB2 transcript levels and cell proliferation (A) PCR primers (arrows) designed to distinguish
More informationConstruction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation
Construction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation J. Du 1, Z.H. Tao 2, J. Li 2, Y.K. Liu 3 and L. Gan 2 1 Department of Chemistry,
More informationGeneration of post-germinal centre myeloma plasma B cell.
Generation of post-germinal centre myeloma. DNA DAMAGE CXCR4 Homing to Lytic lesion activation CD38 CD138 CD56 Phenotypic markers Naive Secondary lymphoid organ Multiple myeloma is a malignancy of s caused
More informationDepartment of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA 2
Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of MicroRNAs 155 and 125b2 Transfection using Nanoparticle Delivery Systems Mei-Ju Su 1, Hibah Aldawsari 2, and Mansoor Amiji
More informationalveolar macrophages (AMs) after 24 hours of in vitro culture in complete medium
Online Supplement for: NF-κB ACTIVATION IN ALVEOLAR MACROPHAGES REQUIRES IκB KINASE-β, BUT NOT NF-κB INDUCING KINASE Supershift and Competition Assays for NF-κB Competition and supershift assays were performed
More informationDeposition of Bone by the Osteoblasts. Bone is continually being deposited by osteoblasts, and it is continually being resorbed where osteoclasts are
Bone remodeling Deposition of Bone by the Osteoblasts. Bone is continually being deposited by osteoblasts, and it is continually being resorbed where osteoclasts are active. This mechanism is always is
More informationSupplemental Material:
Supplemental Material: MATERIALS AND METHODS RNA interference Mouse CHOP sirna (ON-TARGETplus SMARTpool Cat# L-062068-00) and control sirna (ON-TARGETplus Control) were purchased from Dharmacon. Transfection
More informationHEK293FT cells were transiently transfected with reporters, N3-ICD construct and
Supplementary Information Luciferase reporter assay HEK293FT cells were transiently transfected with reporters, N3-ICD construct and increased amounts of wild type or kinase inactive EGFR. Transfections
More informationB16-F10 (Mus musculus skin melanoma), NCI-H460 (human non-small cell lung cancer
Electronic Supplementary Material (ESI) for ChemComm. This journal is The Royal Society of Chemistry 2017 Experimental Methods Cell culture B16-F10 (Mus musculus skin melanoma), NCI-H460 (human non-small
More informationThe Pathogenesis of Bone Erosions in RA FULL VERSION
The Pathogenesis of Bone Erosions in RA FULL VERSION 1 Key Learning Objectives Understand the role of osteoclasts in normal bone remodeling Comprehend the key processes in pathologic osteoclast functions
More informationMouse Glu-OC (undercarboxylated osteocalcin) and Gla-OC (carboxylated osteocalcin) levels were
Supplemental Data Supplemental Materials and Methods Plasma measurements Mouse Glu-OC (undercarboxylated osteocalcin) and Gla-OC (carboxylated osteocalcin) levels were determined using ELISA kits according
More informationNeutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury
Neutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury Bastian OW, Koenderman L, Alblas J, Leenen LPH, Blokhuis TJ. Neutrophils contribute to
More informationL6 GLUT4myc Cell Growth Protocol
L6 GLUT4myc Cell Growth Protocol Background: Parental L6 cells selected for high fusion (2, 3) were stably transfected with a rat GLUT4 cdna carrying a myc epitope (recognized by the commercially available
More informationProtocol for Gene Transfection & Western Blotting
The schedule and the manual of basic techniques for cell culture Advanced Protocol for Gene Transfection & Western Blotting Schedule Day 1 26/07/2008 Transfection Day 3 28/07/2008 Cell lysis Immunoprecipitation
More informationPre-made Reporter Lentivirus for NF-κB Signal Pathway
Pre-made Reporter for NF-κB Signal Pathway Cat# Product Name Amounts LVP965-P or: LVP965-P-PBS NFKB-GFP (Puro) LVP966-P or: LVP966-P-PBS NFKB-RFP (Puro) LVP967-P or: LVP967-P-PBS NFKB-Luc (Puro) LVP968-P
More informationINTRODUCTION. Induction of Monocyte Chemoattractant Protein-1 (MCP-1) Expression by Angiotensin II (AngII) in the Pancreatic Islets and Beta Cells
Induction of Monocyte Chemoattractant Protein-1 (MCP-1) Expression by Angiotensin II (AngII) in the Pancreatic Islets and Beta Cells Galina Chipitsyna, Qiaoke Gong, Chance F. Gray et al. Endocrinology,
More informationProtection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein
Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein Lei Wang 1, Tian-Peng Zhang 1, Yuan Zhang 2, Hai-Lian
More informationSupplementary Figure 1 Role of Raf-1 in TLR2-Dectin-1-mediated cytokine expression
Supplementary Figure 1 Supplementary Figure 1 Role of Raf-1 in TLR2-Dectin-1-mediated cytokine expression. Quantitative real-time PCR of indicated mrnas in DCs stimulated with TLR2-Dectin-1 agonist zymosan
More informationSupplemental information
Carcinoemryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation y Chiang et al. Supplemental
More informationImpact factor: Reporter:4A1H0019 Chen Zi Hao 4A1H0023 Huang Wan ting 4A1H0039 Sue Yi Zhu 4A1H0070 Lin Guan cheng 4A1H0077 Chen Bo xuan
Curcumin Protects Neonatal Rat Cardiomyocytes against High Glucose-Induced Apoptosis via PI3K/Akt Signalling Pathway Wei Yu,1,2 Wenliang Zha,1 Zhiqiang Ke,1 Qing Min,2 Cairong Li,1 Huirong Sun,3 and Chao
More informationSupplementary Material and Methods
Online Supplement Kockx et al, Secretion of Apolipoprotein E from Macrophages 1 Supplementary Material and Methods Cloning of ApoE-GFP Full-length human apoe3 cdna (pcdna3.1/zeo + -apoe) was kindly provided
More informationProgrammed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsrna-induced retinal degeneration
Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsrna-induced retinal degeneration The Harvard community has made this article openly available. Please
More informationCell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice
Supplementary Methods: Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice and gently meshed in DMEM containing 10% FBS to prepare for single cell suspensions. CD4 + CD25
More informationWho manipulates who in dysregulated mineralised tissue resorption? Dr Gurå Therese Bergkvist MRCVS
Who manipulates who in dysregulated mineralised tissue resorption? Dr Gurå Therese Bergkvist MRCVS Senior Lecturer in Veterinary Anatomy & Clinical Research Associate of The Roslin Institute Clinical diseases
More informationCombined Effect of Fluoride and Arsenate on Gene Expression of Osteoclast Differentiation Factor and Osteoprotegerin
BIOMEDICAL AND ENVIRONMENTAL SCIENCES 19, 375-379 (2006) Combined Effect of Fluoride and Arsenate on Gene Expression of Osteoclast Differentiation Factor and Osteoprotegerin LIN JIA 1 AND TAI-YI JIN Department
More informationChia-Lan Tsai 1, Wei-Chung Chen 1, Hsi-Lung Hsieh 2, Pei-Ling Chi 1, Li-Der Hsiao 1 and Chuen-Mao Yang 1,3*
Tsai et al. Journal of Biomedical Science 2014, 21:12 RESEARCH Open Access TNF-α induces matrix metalloproteinase-9- dependent soluble intercellular adhesion molecule-1 release via TRAF2-mediated MAPKs
More informationAdvances in Computer Science Research, volume 59 7th International Conference on Education, Management, Computer and Medicine (EMCM 2016)
7th International Conference on Education, Management, Computer and Medicine (EMCM 2016) Expression of Beta-Adrenergic Receptor in Glioma LN229 Cells and Its Effect on Cell Proliferation Ping Wang1, Qingluan
More informationImpact of hyper-o-glcnacylation on apoptosis and NF-κB activity SUPPLEMENTARY METHODS
SUPPLEMENTARY METHODS 3D culture and cell proliferation- MiaPaCa-2 cell culture in 3D was performed as described previously (1). Briefly, 8-well glass chamber slides were evenly coated with 50 µl/well
More informationm 6 A mrna methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer
SUPPLEMENTARY INFORMATION Articles https://doi.org/10.1038/s41556-018-0174-4 In the format provided by the authors and unedited. m 6 A mrna methylation regulates AKT activity to promote the proliferation
More informationFigure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.
Figure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.129-Gt(ROSA)26Sor tm1(cre/ert2)tyj /J mice. To induce deletion of the Pten locus,
More information(A) RT-PCR for components of the Shh/Gli pathway in normal fetus cell (MRC-5) and a
Supplementary figure legends Supplementary Figure 1. Expression of Shh signaling components in a panel of gastric cancer. (A) RT-PCR for components of the Shh/Gli pathway in normal fetus cell (MRC-5) and
More informationSupporting Information
Supporting Information Desnues et al. 10.1073/pnas.1314121111 SI Materials and Methods Mice. Toll-like receptor (TLR)8 / and TLR9 / mice were generated as described previously (1, 2). TLR9 / mice were
More informationOnline Data Supplement. Anti-aging Gene Klotho Enhances Glucose-induced Insulin Secretion by Upregulating Plasma Membrane Retention of TRPV2
Online Data Supplement Anti-aging Gene Klotho Enhances Glucose-induced Insulin Secretion by Upregulating Plasma Membrane Retention of TRPV2 Yi Lin and Zhongjie Sun Department of physiology, college of
More informationDual effects of baicalin on osteoclast differentiation and bone resorption
Received: 30 December 2017 Revised: 5 June 2018 Accepted: 12 June 2018 DOI: 10.1111/jcmm.13785 ORIGINAL ARTICLE Dual effects of baicalin on osteoclast differentiation and bone resorption Xuanyuan Lu 1
More informationSupplementary Figure 1:
Supplementary Figure 1: (A) Whole aortic cross-sections stained with Hematoxylin and Eosin (H&E), 7 days after porcine-pancreatic-elastase (PPE)-induced AAA compared to untreated, healthy control aortas
More informationMATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All
MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used
More informationPhosphate buffered saline (PBS) for washing the cells TE buffer (nuclease-free) ph 7.5 for use with the PrimePCR Reverse Transcription Control Assay
Catalog # Description 172-5080 SingleShot Cell Lysis Kit, 100 x 50 µl reactions 172-5081 SingleShot Cell Lysis Kit, 500 x 50 µl reactions For research purposes only. Introduction The SingleShot Cell Lysis
More informationTFEB-mediated increase in peripheral lysosomes regulates. Store Operated Calcium Entry
TFEB-mediated increase in peripheral lysosomes regulates Store Operated Calcium Entry Luigi Sbano, Massimo Bonora, Saverio Marchi, Federica Baldassari, Diego L. Medina, Andrea Ballabio, Carlotta Giorgi
More informationThe Schedule and the Manual of Basic Techniques for Cell Culture
The Schedule and the Manual of Basic Techniques for Cell Culture 1 Materials Calcium Phosphate Transfection Kit: Invitrogen Cat.No.K2780-01 Falcon tube (Cat No.35-2054:12 x 75 mm, 5 ml tube) Cell: 293
More informationCharacterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma
Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma Y.-J. Hu 1, X.-Y. Luo 2, Y. Yang 3, C.-Y. Chen 1, Z.-Y. Zhang 4 and X. Guo 1 1 Department
More informationT cell maturation. T-cell Maturation. What allows T cell maturation?
T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry
More informationCytoSelect Tumor- Endothelium Adhesion Assay
Product Manual CytoSelect Tumor- Endothelium Adhesion Assay Catalog Number CBA- 215 100 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Cancer metastasis comprises several
More informationMicroRNA-338-3p inhibits glucocorticoidinduced osteoclast formation through RANKL targeting
MicroRNA-338-3p inhibits glucocorticoidinduced osteoclast formation through RANKL targeting X.H. Zhang 1 *, G.L. Geng 2 *, B. Su 1, C.P. Liang 1, F. Wang 1 and J.C. Bao 3 1 Department of Physical Therapy,
More informationOsteoclast Culture Kit
K-ASSAY Osteoclast Culture Kit For the culture of Osteoclasts from precursor cells. Cat. No.: CC-107 Rat Osteoclast Precursor Cells, V-1 For Research Use Only. 1 Rev. 091708 K-ASSAY PRODUCT INFORMATION
More informationCells and reagents. Synaptopodin knockdown (1) and dynamin knockdown (2)
Supplemental Methods Cells and reagents. Synaptopodin knockdown (1) and dynamin knockdown (2) podocytes were cultured as described previously. Staurosporine, angiotensin II and actinomycin D were all obtained
More information(a) Significant biological processes (upper panel) and disease biomarkers (lower panel)
Supplementary Figure 1. Functional enrichment analyses of secretomic proteins. (a) Significant biological processes (upper panel) and disease biomarkers (lower panel) 2 involved by hrab37-mediated secretory
More informationSupplementary Figure 1. SA-β-Gal positive senescent cells in various cancer tissues. Representative frozen sections of breast, thyroid, colon and
Supplementary Figure 1. SA-β-Gal positive senescent cells in various cancer tissues. Representative frozen sections of breast, thyroid, colon and stomach cancer were stained with SA-β-Gal and nuclear fast
More informationData Sheet IL-2-Luciferase Reporter (Luc) - Jurkat Cell Line Catalog # 60481
642 Cornerstone Court W, Ste B Tel: 1.858.829.382 Data Sheet IL-2-Luciferase Reporter (Luc) - Jurkat Cell Line Catalog # 6481 Description Human IL-2 reporter construct is stably integrated into the genome
More informationAn epithelial-to-mesenchymal transition-inducing potential of. granulocyte macrophage colony-stimulating factor in colon. cancer
An epithelial-to-mesenchymal transition-inducing potential of granulocyte macrophage colony-stimulating factor in colon cancer Yaqiong Chen, Zhi Zhao, Yu Chen, Zhonglin Lv, Xin Ding, Renxi Wang, He Xiao,
More informationSUPPLEMENTARY INFORMATION. Supplementary Figures S1-S9. Supplementary Methods
SUPPLEMENTARY INFORMATION SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane Jian Huang 1,2#, Jie Yan 1,2#, Jian Zhang 3#, Shiguo Zhu 1, Yanli Wang
More informationIslet viability assay and Glucose Stimulated Insulin Secretion assay RT-PCR and Western Blot
Islet viability assay and Glucose Stimulated Insulin Secretion assay Islet cell viability was determined by colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay using CellTiter
More informationArgininosuccinate synthetase 1 suppression and arginine restriction inhibit cell
Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines Yan-Shen Shan 1, Hui-Ping Hsu 1, Ming-Derg Lai 2,3, Meng-Chi Yen 2,4, Wei-Ching Chen
More informationNature Medicine: doi: /nm.4324
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Supplementary Figure 1. Kinetics of SnCs development in surgically-induced OA and effect of GCV-induced SnC clearance on OA disease progression
More informationOsteoclasts- What Do They Do and How Do They Do It? Prof. Steven L. Teitelbaum
Osteoclasts; What Do They Do 1 Steven L. Teitelbaum, M.D. Wilma and Roswell Messing Professor Department of Pathology and Immunology Washington University School of Medicine OSTEOCLASTS OSTEOBLASTS 2 Osteoclasts
More informationTRACP & ALP Assay Kit
Cat. # MK301 For Research Use TRACP & ALP Assay Kit Product Manual Table of Contents I. Description...3 II. III. IV. Introduction...3 Components...4 Materials Required but not Provided...4 V. Storage...4
More informationSuppl Video: Tumor cells (green) and monocytes (white) are seeded on a confluent endothelial
Supplementary Information Häuselmann et al. Monocyte induction of E-selectin-mediated endothelial activation releases VE-cadherin junctions to promote tumor cell extravasation in the metastasis cascade
More informationExosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signalling pathway
Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signalling pathway Jieyuan Zhang, Xiaolin Liu, Haiyan Li, Chunyuan Chen, Bin Hu, Xin Niu, Qing
More informationSupplementary Figure 1. The mir-182 binding site of SMAD7 3 UTR and the. mutated sequence.
Supplementary Figure 1. The mir-182 binding site of SMAD7 3 UTR and the mutated sequence. 1 Supplementary Figure 2. Expression of mir-182 and SMAD7 in various cell lines. (A) Basal levels of mir-182 expression
More informationSupplementary Information POLO-LIKE KINASE 1 FACILITATES LOSS OF PTEN-INDUCED PROSTATE CANCER FORMATION
Supplementary Information POLO-LIKE KINASE 1 FACILITATES LOSS OF PTEN-INDUCED PROSTATE CANCER FORMATION X. Shawn Liu 1, 3, Bing Song 2, 3, Bennett D. Elzey 3, 4, Timothy L. Ratliff 3, 4, Stephen F. Konieczny
More informationSunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic
Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myeogenouse leukemia cells that is enhanced by 1,25-dihydroxyviatmin D 3. To the Editor: Sunitinib,
More informationStudy on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value
Study on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value Shen Wei 1,a, Chen Juan 2, Li Xiurong 1 and Yin Jie 1 1 Department of Obstetrics and Gynecology,
More informationSupplemental Materials. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in. Pancreatic Cancer.
Supplemental Materials Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer Jun Zhao 1, Zhilan Xiao 2, 3, Tingting Li 1, 4, Huiqin Chen 5, Ying Yuan 5, Alan
More informationReduction of metastatic and angiogenic potency of malignant cancer by Eupatorium. fortunei via suppression of MMP-9 activity and VEGF production
Supplementary Information Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production Aeyung Kim, Minju Im, Nam-Hui Yim
More informationTITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets
AD Award Number: W81XWH-05-1-0166 TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets PRINCIPAL INVESTIGATOR: Alice C. Levine, M.D. CONTRACTING ORGANIZATION: Mount Sinai School of Medicine
More informationElectron micrograph of phosphotungstanic acid-stained exosomes derived from murine
1 SUPPLEMENTARY INFORMATION SUPPLEMENTARY FIGURES Supplementary Figure 1. Physical properties of murine DC-derived exosomes. a, Electron micrograph of phosphotungstanic acid-stained exosomes derived from
More informationSupplementary Materials and Methods
Supplementary Materials and Methods Immunoblotting Immunoblot analysis was performed as described previously (1). Due to high-molecular weight of MUC4 (~ 950 kda) and MUC1 (~ 250 kda) proteins, electrophoresis
More informationORIGINAL PAPER DISRUPTION OF CELL SPREADING BY THE ACTIVATION OF MEK/ERK PATHWAY IS DEPENDENT ON AP-1 ACTIVITY
Nagoya J. Med. Sci. 72. 139 ~ 144, 1 ORIGINAL PAPER DISRUPTION OF CELL SPREADING BY THE ACTIVATION OF MEK/ERK PATHWAY IS DEPENDENT ON AP-1 ACTIVITY FENG XU, SATOKO ITO, MICHINARI HAMAGUCHI and TAKESHI
More informationhttp / / cjbmb. bjmu. edu. cn Chinese Journal of Biochemistry and Molecular Biology COX-2 NTera-2 NTera-2 RT-PCR FasL caspase-8 caspase-3 PARP.
ISSN 1007-7626 CN 11-3870 / Q http / / cjbmb bjmu edu cn Chinese Journal of Biochemistry and Molecular Biology 2012 7 28 7 630 ~ 636 NTera-2 ** ** * 410081 COX-2 NTera-2 MTT NTera-2 NTera-2 Hoechest 33258
More information